Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects

Neuroendocrinology

Volumn 101, Issue 4, 2015, Pages 274-288

  Koumarianou, Anna ^a   Kaltsas, Gregory ^b   Kulke, Matthew H ^c   Oberg, Kjell ^e   Strosberg, Jonathan R ^d   Spada, Francesca ^f   Galdy, Salvatore ^f   Barberis, Massimo ^f   Fumagalli, Caterina ^f   Berruti, Alfredo ^g   Fazio, Nicola ^f  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Ki 67 labelling index; Neuroendocrine carcinomas; Neuroendocrine neoplasms; Pancreatic neuroendocrine neoplasms; Progression free survival

Indexed keywords

BIOLOGICAL MARKER; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL FEATURE; DRUG PROTEIN BINDING; DRUG SAFETY; HUMAN; MULTICENTER STUDY (TOPIC); NEUROENDOCRINE TUMOR; PARAGANGLIOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); THORAX TUMOR; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; NEUROENDOCRINE TUMORS;

ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; HUMANS; NEUROENDOCRINE TUMORS;

EID: 84937968301     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000430816     Document Type: Article

References (86)

1. Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959.
2. Modlin IM, Moss SF, Gustafsson BI, Lawrence B, Schimmack S, Kidd M: The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant. Langenbecks Arch Surg 2011; 396: 1145-1156.
3. Klöppel G: Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2011; 18(suppl 1):S1-S16.
4. Rindi G, Arnold R, Bosman F, Capella C, Klimstra D, Klöppel G, Komminoth P, Solcia E: Nomenclature and classification of neuroendocrine neoplasms of the digestive system; in Bosman FT, Carneiro F, Hruban RH, Theise ND (eds): WHO Classification of Tumours of the Digestive System. Lyon, IARC, 2010, pp 13-14.
5. Basu B, Sirohi B, Corrie P: Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin. Endocr Relat Cancer 2010; 17:R75-R90.
6. Koumarianou A, Chatzellis E, Boutzios G, Tsavaris N, Kaltsas G: Current concepts in the diagnosis and management of poorly differentiated gastrointestinal neuroendocrine carcinomas. Endokrynol Pol 2013; 64: 60-72.
7. Fazio N, Spada F, Giovannini M: Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view. Cancer Treat Rev 2013; 39: 270-274.
8. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513.
9. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
10. de Mestier L, Dromain C, d'Assignies G, Scoazec JY, Lassau N, Lebtahi R, Brixi H, Mitry E, Guimbaud R, Courbon F, d'Herbomez M, Cadiot G: Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocr Relat Cancer 2014; 21:R105-R120.
11. Öberg K, Akerström G, Rindi G, Jelic S: Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(suppl 5):v223-v227.
12. Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B, Salazar R: ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95: 157-176.
13. Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, Déandreis D, Borget I, Loriot C, Chougnet C, Letouzé E, Young J, Amar L, Bertherat J, Libé R, Dumont F, Deschamps F, Schlumberger M, Gimenez-Roqueplo AP, Baudin E: SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer 2014; 135: 2711-2720.
14. Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, François P, Jouanneau E, Passagia JG, Bernier M, Cornélius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T: Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 2010; 95: 4592-4599.
15. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L: First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268-275.
16. Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Öberg K: Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011; 117: 4617-4622.
17. Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS, Redston MS: O 6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009; 15: 338-345.
18. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C: Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997; 23: 35-61.
19. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M, Glaser M, Brampton MH, Rustin GJ: Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998; 58: 4363-4367.
20. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, Quarterman CP, Hoffman R, Stevens MF, Brampton MH, et al: Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992; 65: 287-291.
21. Jen JF, Cutler DL, Pai SM, Batra VK, Affrime MB, Zambas DN, Heft S, Hajian G: Population pharmacokinetics of temozolomide in cancer patients. Pharm Res 2000; 17: 1284-1289.
22. Darkes JM, Plosker G, Jarvis B: Temozolomide: a review of its use in the treatment of malignant gliomas, malignant melanoma and other advanced cancers. Am J Cancer 2002; 1: 55-80.
23. Wedge SR, Newlands ES: O 6-benzylguanine enhances the sensitivity of a glioma xenograft with low O 6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br J Cancer 1996; 73: 1049-1052.
24. Taverna P, Liu L, Hanson AJ, Monks A, Gerson SL: Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother Pharmacol 2000; 46: 507-516.
25. Boulton S, Pemberton LC, Porteous JK, Curtin NJ, Griffin RJ, Golding BT, Durkacz BW: Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer 1995; 72: 849-856.
26. Ryu CH, Yoon WS, Park KY, Kim SM, Lim JY, Woo JS, Jeong CH, Hou Y, Jeun SS: Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. J Biomed Biotechnol 2012; 2012: 987495.
27. Natarajan AT, Vermeulen S, Darroudi F, Valentine MB, Brent TP, Mitra S, Tano K: Chromosomal localization of human O 6-methylguanine-DNA methyltransferase (MGMT) gene by in situ hybridization. Mutagenesis 1992; 7: 83-85.
28. Shiraishi A, Sakumi K, Sekiguchi M: Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase. Carcinogenesis 2000; 21: 1879-1883.
29. Kaina B, Christmann M, Naumann S, Roos WP: MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 2007; 6: 1079-1099.
30. Gilbert JA, Adhikari LJ, Lloyd RV, Halfdanarson TR, Muders MH, Ames MM: Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. Pancreas 2013; 42: 411-421.
31. Chan AO, Kim SG, Bedeir A, Issa JP, Hamilton SR, Rashid A: CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 2003; 22: 924-934.
32. Arnold CN, Sosnowski A, Schmitt-Graff A, Arnold R, Blum HE: Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system. Int J Cancer 2007; 120: 2157-2164.
33. Nakasu S, Fukami T, Baba K, Matsuda M: Immunohistochemical study for O 6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas. J Neurooncol 2004; 70: 333-340.
34. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Örlefors H, Sigurd M, Öberg K, Eriksson B, Skogseid B: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007; 13: 2986-2991.
35. Preusser M, Janzer CR, Felsberg J, Reifenberger G, Hamou MF, Diserens AC, Stupp R, Gorlia T, Marosi C, Heinzl H, Hainfellner JA, Hegi M: Anti-O 6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 2008; 18: 520-532.
36. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
37. Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W: MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin Cancer Res 2015; 21: 2057-2064.
38. Walter T, van Brakel B, Vercherat C, Hervieu V, Forestier J, Chayvialle JA, Molin Y, Lombard-Bohas C, Joly MO, Scoazec JY: O 6-methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents. Br J Cancer 2015; 112: 523-531.
39. Strosberg J, Cives M, Brelsford M, Black M, Meeker A, Ghayouri M: Identification of response predictors to temozolomide-based chemotherapy (H16 poster). 12th Annual Conference European Neuroendocrine Tumor Society, Barcelona, 2015.
40. Broder LE, Carter SK: Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973; 79: 108-118.
41. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326: 519-523.
42. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22: 4762-4771.
43. Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J, Kayani I, Toumpanakis C, Grillo F, Mayer A, Hochhauser D, Begent RH, Caplin ME, Meyer T: Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010; 102: 1106-1112.
44. Ramanathan RK, Cnaan A, Hahn RG, Carbone PP, Haller DG: Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001; 12: 1139-1143.
45. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006; 24: 401-406.
46. Koumarianou A, Antoniou S, Kanakis G, Economopoulos N, Rontogianni D, Ntavatzikos A, Tsavaris N, Pectasides D, Dimitriadis G, Kaltsas G: Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours. Endocr Relat Cancer 2012; 19:L1-L4.
47. Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA, Zheng H, Fuchs CS, Kulke MH: Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 2012; 30: 2963-2968.
48. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, Goetz AD, Schwartz G, Edwards T, Reyderman L, Statkevich P, Cutler DL, Rowinsky EK: Marked inactivation of O 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003; 88: 1004-1011.
49. Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4: 423-436.
50. Olsen IH, Sørensen JB, Federspiel B, Kjaer A, Hansen CP, Knigge U, Langer SW: Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas. ScientificWorldJournal 2012; 2012: 170496.
51. Chan JA, Blaszkowsky L, Stuart K, Zhu AX, Allen J, Wadlow R, Ryan DP, Meyerhardt J, Gonzalez M, Regan E, Zheng H, Kulke MH: A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer 2013; 119: 3212-3218.
52. Fine R, Fogelman D, Schreibman S: Effective treatment of neuroendocrine tumors with capecitabine and temozolomide (abstract 4216). ASCO Gastrointestinal Cancers Symposium. J Clin Oncol 2005; 23: 16S.
53. Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S, Tsushima DA, Mowatt KB, Dinnen RD, Mao Y, Stevens PD, Schrope B, Allendorf J, Lee JA, Sherman WH, Chabot JA: Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: the Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol 2013; 71: 663-670.
54. Murakami J, Lee YJ, Kokeguchi S, Tsujigiwa H, Asaumi J, Nagatsuka H, Fukui K, Kuroda M, Tanaka N, Matsubara N: Depletion of O 6-methylguanine-DNA methyltransferase by O 6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines. Oncol Rep 2007; 17: 1461-1467.
55. Spiro TP, Liu L, Majka S, Haaga J, Willson JK, Gerson SL: Temozolomide: the effect of onceand twice-a-day dosing on tumor tissue levels of the DNA repair protein O 6-alkylguanine-DNA-alkyltransferase. Clin Cancer Res 2001; 7: 2309-2317.
56. Saif MW, Kaley K, Brennan M, Garcon MC, Rodriguez G, Rodriguez T: A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. JOP 2013; 14: 498-501.
57. Fine R, Gulati A, Tsushima D, Mowatt K, Oprescu A, Bruce J, Chabot J: Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors. ASCO Gastrointestinal Cancers Symposium 2014. J Clin Oncol 2014; 32(suppl 3):abstract 179.
58. Spada F, Fumagalli C, Antonuzzo L, Messerini L, Radice D, Di Rocco R, Galdy S, Barucca V, Pisa E, Barberis M, Di Costanzo F, Fazio N: Capecitabine plus temozolomide (CAPTEM) in patients with advanced neuroendocrine neoplasms (NEN): an Italian multicenter retrospective analysis. ASCO Gastrointestinal Cancers Symposium 2014. J Clin Oncol 2014; 32(suppl 3):abstract 281.
59. Peixoto R, Noonan R, Kennecke H, Lim H: Outcomes of patients treated with capecitabine and temozolamide (CAPTEM) for advanced pancreatic neuroendocrine tumors (pNETs) and non-pNETs. ASCO Gastrointestinal Cancers Symposium 2014. J Clin Oncol 2014; 32(suppl 3):abstract 343.
60. Claringbold PG, Price RA, Turner JH: Phase I-II study of radiopeptide 177 Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. Cancer Biother Radiopharm 2012; 27: 561-569.
61. Moertel CG, Kvols LK, O'Connell MJ, Rubin J: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227-232.
62. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U: Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013; 24: 152-160.
63. Crona J, Fanola I, Lindholm DP, Antonodimitrakis P, Öberg K, Eriksson B, Granberg D: Effect of temozolomide in patients with metastatic bronchial carcinoids. Neuroendocrinology 2013; 98: 151-155.
64. Saranga-Perry V, Morse B, Centeno B, Kvols L, Strosberg J: Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series. Neuroendocrinology 2013; 97: 318-321.
65. Crona J, Björklund P, Welin S, Kozlovacki G, Öberg K, Granberg D: Treatment, prognostic markers and survival in thymic neuroendocrine tumours. A study from a single tertiary referral centre. Lung Cancer 2013; 79: 289-293.
66. Chong CR, Wirth LJ, Nishino M, Chen AB, Sholl LM, Kulke MH, McNamee CJ, Jänne PA, Johnson BE: Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. Lung Cancer 2014; 86: 241-246.
67. Pietanza MC, Kadota K, Huberman K, Sima CS, Fiore JJ, Sumner DK, Travis WD, Heguy A, Ginsberg MS, Holodny AI, Chan TA, Rizvi NA, Azzoli CG, Riely GJ, Kris MG, Krug LM: Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res 2012; 18: 1138-1145.
68. Zauderer MG, Drilon A, Kadota K, Huberman K, Sima CS, Bergagnini I, Sumner DK, Travis WD, Heguy A, Ginsberg MS, Holodny AI, Riely GJ, Kris MG, Krug LM, Pietanza MC: Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. Lung Cancer 2014; 86: 237-240.
69. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB: The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2007; 14: 569-585.
70. Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB: Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 2004; 151: 15-27.
71. Bravo EL, Kalmadi SR, Gill I: Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report. Horm Metab Res 2009; 41: 703-706.
72. Nozières C, Walter T, Joly MO, Giraud S, Scoazec JY, Borson-Chazot F, Simon C, Riou JP, Lombard-Bohas C: A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine. Eur J Endocrinol 2012; 166: 1107-1111.
73. Payne MJ, Pratap SE, Middleton MR: Temozolomide in the treatment of solid tumours: current results and rationale for dosing/ scheduling. Crit Rev Oncol Hematol 2005; 53: 241-252.
74. Oberstein P, Gulati A, Krantz B, Moss R, Schreibman S, Tsushima D, Mowatt K, Allendorf J, Schrope B, Lee J, Sherman W, Chabot J, Fine R: The efficacy and safety of the capecitabine/temozolomide (CAPTEM) regimen in the treatment of well-differentiated neuroendocrine tumors with liver metastasis after failure of previous therapy: Columbia University Medical Center Experience. ASCO Gastrointestinal Cancers Symposium 2013. J Clin Oncol 2013; 31(suppl 4):abstract 308.
75. Ganetsky A, Adel N, Do GK, Reidy D: The efficacy of capecitabine and temozolomide for the treatment of metastatic neuroendocrine tumors: Memorial Sloan-Kettering Cancer Center experience. ASCO Gastrointestinal Cancers Symposium 2012. J Clin Oncol 2012; 30(suppl 4):abstract 363.
76. Neyns B, Tosoni A, Hwu WJ, Reardon DA: Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer 2010; 116: 2868-2877.
77. Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C, Williams L, Foster T, Sepkowitz KA, Chapman PB: Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004; 22: 610-616.
78. Dresemann G: Temozolomide in malignant glioma. Onco Targets Ther 2010; 3: 139-146.
79. de Bono J, Denis L, Patnaik A, Hammond L, Geyer E, Gerson E, Cutler D, Reyderman I, Rowinsky E, Tolcher A: Extended temozolomine (TMZ) dosing schedules permit the administration of higher TMZ dose intensities and inhibit the DNA repair enzyme O 6-alkylguanine DNA alkyltransferase (AGAT). Eur J Cancer 2001; 37(suppl 6):S31-S32.
80. Neyns B, Chaskis C, Joosens E, Menten J, D'Hondt L, Branle F, Sadones J, Michotte A: A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. Cancer Invest 2008; 26: 269-277.
81. Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I: Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol 2013; 15: 242-250.
82. Jalali R, Singh P, Menon H, Gujral S: Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with temozolomide. J Neurooncol 2007; 85: 105-107.
83. Noronha V, Berliner N, Ballen KK, Lacy J, Kracher J, Baehring J, Henson JW: Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature. Neuro Oncol 2006; 8: 280-283.
84. Su YW, Chang MC, Chiang MF, Hsieh RK: Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neurooncol 2005; 71: 315-318.
85. Villano JL, Collins CA, Manasanch EE, Ramaprasad C, van Besien K: Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol 2006; 7: 436-438.
86. Kesavan M, Claringbold PG, Turner JH: Hematological toxicity of combined Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up. Neuroendocrinology 2014; 99: 108-117.